| Literature DB >> 14552157 |
Abstract
Gastritis--inflammation of the stomach--is a frequently cited differential yet rarely characterized diagnosis in cases of canine anorexia and vomiting. Although the list of rule-outs for acute or chronic gastritis is extensive, a review of the veterinary literature reveals fewer than 15 articles that have focused on clinical cases of canine gastritis over the last 25 years. The dog frequently appears in the human literature as an experimentally manipulated model for the study of endoscopic techniques or the effect of medications on gastric mucosa. In the veterinary patient, cases of acute gastritis are rarely pursued with the complete diagnostic armamentarium, and cases of chronic gastritis are rarely found to occur as an entity isolated from the rest of the gastrointestinal tract. This article focuses on those findings most clinically relevant to cases of canine gastritis in veterinary medicine.Entities:
Mesh:
Year: 2003 PMID: 14552157 PMCID: PMC7124327 DOI: 10.1016/s0195-5616(03)00052-4
Source DB: PubMed Journal: Vet Clin North Am Small Anim Pract ISSN: 0195-5616 Impact factor: 2.093
Fig. 1Function of prostaglandin products formed from arachidonic acid through cyclooxygenase COX-1 and COX-2 enzymatic pathways.
Drugs frequently used in the treatment of canine gastritis
| Drug | Class | Mechanism of action |
|---|---|---|
| Cimetidine | H2-receptor antagonist | Competitively inhibits histamine binding to parietal cell H2 receptors—inhibits gastric acid secretion |
| Ranitidine | H2-receptor antagonist | Inhibits acid secretion to greater extent than cimetidine, prokinetic (acetylcholinesterase inhibition), increase LES pressure |
| Famotidine | H2-receptor antagonist | Similar in potency to ranitidine, no prokinetic or LES effects |
| Nizatidine | H2-receptor antagonist | Similar to ranitidine |
| Misoprostol | Prostaglandin E1 analogue | Inhibits adenylate cyclase, reducing cAMP and protein kinase-dependent H+ production, cytoprotective, increases bicarbonate secretion and mucosal blood flow |
| Omeprazole | Proton pump inhibitor | Inhibits patients cell H+/K+ ATPase enzyme—more potent gastric acid inhibition than with H2-receptor antagonists |
| Sucralfate | Basic aluminum salt of sulfated sucrose | Cytoprotective; selectively binds to ulcerated tissue, binds bile and pepsin, stimulates bicarbonate and prostaglandin E2 secretion, reduces parietal cell responsiveness, preserves mucosal blood flow. |
| Metoclopramide | Antiemetic, prokinetic | Stimulates upper gastrointestinal motility (acetylcholine sensitization), increases LES pressure; dopamine antagonist in CRTZ |
| Domperidone (not yet approved in United States) | Antiemetic, prokinetic | Dopamine antagonist, similar in action to metoclopramide |
| Diphenhydramine | Antihistamine, Antiemetic | Completively inhibits histamine binding to H1 receptors |
| Chlorpromazine | Antiemetic | Phenothiazine derivative, inhibition of CRTZ and emetic center |
| Prochlorperazine | Antiemetic | Phenothiazine derivative, inhibition of CRTZ and emetic center |
| Ondansetron | Antiemetic | 5-HT3 receptor antagonist at periphery and CRTZ |
| Cispride (if available) | Prokinetic | Accelerates gastric emptying, increases LES pressure (enhanced acetylcholine release) |
| Colloidal bismuth | Protectant | Chelates proteinaceous material at the base of an ulcer, complexes with mucoglycoproteins to provide additional diffusion barrier to acid |
Abbreviations: ATPase, adenosine triphosphatase; cAMP, cyclic adenosine monophosphate; CRTZ, chemoreceptor trigger zone; LES, lower esophageal sphincter.